2023-08-22 14:17:33
22/08/2023
Target audiences: Research professionals
Themes: Research
On June 14, 2023 in Paris, on the sidelines of the 6th Franco-International Oncology Days (IFODS), a joint INCa/IFODS session on clinical research brought together investigators, oncologist researchers and medical students around 7 projects funded as part of the Hospital Program for Clinical Cancer Research (PHRC-K), managed by the National Cancer Institute.
This restitution seminar made it possible to present the progress and feedback from 7 clinical research projects. These projects were selected by the PHRC-K between 2011 and 2019, and funded to the tune of 2.8 million euros in total.
Throughout the morning, the principal investigators or their representatives took turns at the podium, welcomed by Professor Jean-Philippe Spano (CHU La Pitié Salpêtrière, Paris), who chaired the seminar. Dr Lætitia Gambotti, head of the Institute’s clinical research department (INCa, Boulogne-Billancourt), introduced the seminar by presenting the public funding of clinical research in oncology.
The following works have been reported:
Lung ART – Phase III trial comparing postoperative conformal mediastinal radiotherapy with no radiotherapy following complete surgery in patients with non-small cell lung carcinoma (NSCLC) with N2 mediastinal invasion, by Cécile Le Pechoux (Gustave Roussy , Villejuif – PHRC-K 2012).
The results of this study were published in the Lancet Oncology in 2022. ESTIMABL2 – Low-risk differentiated thyroid cancer: is ablative treatment with iodine 131 useful? by Isabelle Borget (Gustave Roussy, Villejuif – PHRC-K 2012).
The results of the clinical trial have been published in the New England Journal of Medicine in 2022. PAZOTHYR- Randomized phase II study to evaluate the efficacy of pazopanib/paclitaxel treatment versus paclitaxel alone for the treatment of metastatic and/or relapsed anaplastic thyroid cancers following initial treatment, by Christelle De La Fouchardière, (Institut Paoli-Calmette, Marseille – PHRC-K 2011).
The results of this study were published in the Journal of Clinical Oncologyin 2021. IMHOTEP 01 – Neoadjuvant immunotherapy in MSI/dMMR tumours, by Christelle De La Fouchardière, (Institut Paoli-Calmette, Marseille – PHRC-K 2019).
This study is in the process of including patients. MIRs 03 – Phase IV, multicenter, double-blind, randomized clinical trial evaluating the effect of paravertebral blockade with ropivacaine on chronic pain following oncological breast surgery, by Aline Albi-Feldzer (Institut Curie, Paris – PHRC- K 2013).
The results of this clinical trial have been published in Anesthesiology in 2021. MIRs 04 – Randomized, multicenter, double-blind clinical trial evaluating the effect of interpectoral nerve block (Pecs 1 and 2) with ropivacaine versus placebo on acute pain following oncological breast surgery, by Aline Albi-Feldzer (Institut Curie, Paris – PHRC-K 2018).
This study is ongoing. EPIC-2015 – Impact on survival of early palliative care in metastatic cancers of the upper digestive tract (pancreas, bile ducts and gastric) treated with chemotherapy – Randomized phase III study, by Marie-Cécile Le Deley (Institut Oscar Lambret, Lille – PHRC-K 2016).
The first results showed that, in patients treated for metastatic cancer of the upper digestive tract, the introduction of early palliative care visits is not associated with an improvement in overall survival compared to standard care.
Beyond the reported results, this seminar allowed an exchange of experiences around the prerequisites for the smooth running of a clinical trial. The speakers also shared their common difficulties and those inherent to the specialty of the project (support care, anesthesia, etc.). One of the important points noted by all the speakers is that a good involvement of the investigating centers in the inclusion of patients was necessary for the outcome of a clinical study.
1692714338
#Restitution #seminar #Hospital #Program #Clinical #Research #Cancer #PHRCK